TheraRadar
← Back
Data updated: Jun 28, 2026

RISING PHARMS

Generics

RISING PHARMS is a generic drug manufacturer focused on Respiratory.

2022
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

RISING PHARMS's Key Drugs

RISING PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

RISING PHARMS's Recent FDA Approvals

New NDA/BLA approvals for RISING PHARMS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

RISING PHARMS's Therapeutic Areas

RISING PHARMS's approved drugs and pipeline span 1 therapeutic area, led by Respiratory. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Respiratory 100%
1 drugs

RISING PHARMS's Top Competitors

RISING PHARMS's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and GSK. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

RISING PHARMS Pipeline Snapshot

Active clinical trials for RISING PHARMS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Respiratory pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling